Kuros Biosciences has been granted the European patent EP 3268058, “Osteoinductive composites.” This patent covers certain combinations of polymers and granular materials, and further expands Kuros’s patent portfolio relating to its MagnetOs product line. The company also received notice of allowance of a patent application from the same patent family in Japan.
MagnetOs bone graft putty comprises MagnetOs Granules premixed with a polymeric binder for application in simple and complex bony defects in the spine. After implantation, the polymeric binder in the putty is rapidly resorbed, leaving the granules to guide three-dimensional bone regeneration.
Kuros has over 20 granted patents and more than 10 patents pending, specifically in the field of bone graft technologies.
Joost de Bruijn, Chief Executive Officer, said, “Our mission at Kuros is to eliminate orthopedic non-unions in the spine and improve patient rehabilitation after back surgery. Granting of these patents further demonstrates Kuros’s position as a leader in the field of orthobiologics with innovative spinal products.”
Kuros Biosciences has been granted the European patent EP 3268058, "Osteoinductive composites." This patent covers certain combinations of polymers and granular materials, and further expands Kuros’s patent portfolio relating to its MagnetOs product line. The company also received notice of allowance of a patent application from the same...
Kuros Biosciences has been granted the European patent EP 3268058, “Osteoinductive composites.” This patent covers certain combinations of polymers and granular materials, and further expands Kuros’s patent portfolio relating to its MagnetOs product line. The company also received notice of allowance of a patent application from the same patent family in Japan.
MagnetOs bone graft putty comprises MagnetOs Granules premixed with a polymeric binder for application in simple and complex bony defects in the spine. After implantation, the polymeric binder in the putty is rapidly resorbed, leaving the granules to guide three-dimensional bone regeneration.
Kuros has over 20 granted patents and more than 10 patents pending, specifically in the field of bone graft technologies.
Joost de Bruijn, Chief Executive Officer, said, “Our mission at Kuros is to eliminate orthopedic non-unions in the spine and improve patient rehabilitation after back surgery. Granting of these patents further demonstrates Kuros’s position as a leader in the field of orthobiologics with innovative spinal products.”
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
